Tag: JNJ

HBK Sorce Advisory LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 4.5% in the second quarter, HoldingsChannel reports. The firm owned 53,703 shares of the company’s stock after selling 2,517 shares during the period. HBK Sorce Advisory LLC’s holdings in Johnson & Johnson were worth $7,849,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Gilbert & Cook Inc. raised its stake in Johnson & Johnson by 3.3% in the 4th quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock valued at $1,428,000 after purchasing an additional 288 shares during the last quarter. 9258 Wealth Management LLC boosted its position in Johnson & Johnson by 2.1% during the fourth quarter. 9258 Wealth Management LLC now owns 22,034 shares of the company’s stock worth $3,454,000 after acquiring an additional 443 shares during the last quarter. Gryphon Financial Partners LLC raised its holdings in Johnson & Johnson by 66.3% in the 4th quarter. Gryphon Financial Partners LLC now owns 14,245 shares of the company’s stock valued at $2,244,000 after acquiring an additional 5,680 shares during the last quarter. Wade G W & Inc. lifted its stake in Johnson & Johnson by 0.6% in the 4th quarter. Wade G W & Inc. now owns 217,026 shares of the company’s stock worth $34,017,000 after purchasing an additional 1,332 shares in the last quarter. Finally, Inceptionr LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $404,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on JNJ shares. Sanford C. Bernstein lifted their price objective on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. The Goldman Sachs Group lowered their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research note on Tuesday, July 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, September 9th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $173.21.

Read Our Latest Stock Analysis on JNJ

Johnson & Johnson Stock Up 0.5 %

Shares of JNJ opened at $165.52 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The stock has a market capitalization of $398.45 billion, a PE ratio of 10.32, a P/E/G ratio of 2.71 and a beta of 0.53. The company’s 50-day simple moving average is $159.55 and its 200-day simple moving average is $153.99. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter last year, the company posted $2.80 EPS. The firm’s revenue was up 4.3% compared to the same quarter last year. Analysts forecast that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.00%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Tweedy Browne Co LLC cut its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,133,725 shares of the company’s stock after selling 1,393 shares during the quarter. Johnson & Johnson makes up approximately 8.4% of Tweedy Browne Co LLC’s portfolio, making the stock its 3rd largest holding. Tweedy Browne Co LLC’s holdings in Johnson & Johnson were worth $179,344,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of JNJ. Pathway Financial Advisors LLC raised its position in shares of Johnson & Johnson by 4.3% during the 4th quarter. Pathway Financial Advisors LLC now owns 5,438 shares of the company’s stock valued at $852,000 after buying an additional 226 shares during the period. Daiwa Securities Group Inc. lifted its stake in shares of Johnson & Johnson by 5.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 297,850 shares of the company’s stock valued at $46,685,000 after purchasing an additional 15,490 shares during the last quarter. OneAscent Financial Services LLC grew its holdings in shares of Johnson & Johnson by 82.8% during the 4th quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company’s stock worth $1,542,000 after purchasing an additional 4,457 shares during the period. Drive Wealth Management LLC increased its position in shares of Johnson & Johnson by 4.5% during the 1st quarter. Drive Wealth Management LLC now owns 9,625 shares of the company’s stock worth $1,523,000 after purchasing an additional 414 shares during the last quarter. Finally, Vestmark Advisory Solutions Inc. lifted its position in Johnson & Johnson by 12.7% in the fourth quarter. Vestmark Advisory Solutions Inc. now owns 19,587 shares of the company’s stock valued at $3,070,000 after buying an additional 2,201 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.1 %

Shares of NYSE:JNJ opened at $149.88 on Friday. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The firm has a 50 day simple moving average of $147.94 and a 200-day simple moving average of $153.50. The company has a market capitalization of $360.71 billion, a PE ratio of 9.34, a P/E/G ratio of 2.49 and a beta of 0.52. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. During the same quarter in the prior year, the firm posted $2.68 earnings per share. Johnson & Johnson’s revenue for the quarter was up 2.3% on a year-over-year basis. On average, equities analysts predict that Johnson & Johnson will post 10.61 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.31%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent analyst reports. Morgan Stanley decreased their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. The Goldman Sachs Group began coverage on Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target for the company. Bank of America decreased their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research report on Monday, June 17th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 30th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $174.07.

Read Our Latest Stock Report on JNJ

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Burke & Herbert Bank & Trust Co. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 18.4% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 22,909 shares of the company’s stock after selling 5,164 shares during the quarter. Johnson & Johnson accounts for approximately 2.9% of Burke & Herbert Bank & Trust Co.’s investment portfolio, making the stock its 6th biggest holding. Burke & Herbert Bank & Trust Co.’s holdings in Johnson & Johnson were worth $3,568,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. BlackRock Inc. lifted its stake in shares of Johnson & Johnson by 1.4% during the first quarter. BlackRock Inc. now owns 201,491,567 shares of the company’s stock worth $31,231,193,000 after buying an additional 2,688,798 shares during the period. State Street Corp lifted its stake in shares of Johnson & Johnson by 1.1% during the second quarter. State Street Corp now owns 141,833,756 shares of the company’s stock worth $23,476,323,000 after buying an additional 1,568,633 shares during the period. Moneta Group Investment Advisors LLC raised its holdings in shares of Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after purchasing an additional 54,326,454 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Johnson & Johnson by 2.0% during the second quarter. Geode Capital Management LLC now owns 49,697,798 shares of the company’s stock worth $8,203,608,000 after purchasing an additional 990,298 shares during the last quarter. Finally, Morgan Stanley raised its holdings in shares of Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after purchasing an additional 4,521,062 shares during the last quarter. 68.40% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on JNJ. Cantor Fitzgerald reissued an “overweight” rating on shares of Johnson & Johnson in a report on Monday, December 18th. Wells Fargo & Company cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. Royal Bank of Canada reissued an “outperform” rating and set a $178.00 target price on shares of Johnson & Johnson in a report on Friday, December 1st. Finally, Raymond James cut their price objective on shares of Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating for the company in a report on Wednesday, October 18th. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $168.75.

Read Our Latest Stock Report on JNJ

Johnson & Johnson Stock Up 0.2 %

Shares of NYSE JNJ opened at $156.61 on Friday. The company’s 50-day simple moving average is $152.48 and its 200-day simple moving average is $159.60. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $180.93. The firm has a market cap of $377.00 billion, a price-to-earnings ratio of 11.63, a price-to-earnings-growth ratio of 3.20 and a beta of 0.57. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Tuesday, October 17th. The company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.14. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. The business had revenue of $21.35 billion for the quarter, compared to analyst estimates of $21 billion. Equities analysts predict that Johnson & Johnson will post 9.96 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 5th. Stockholders of record on Tuesday, November 21st were given a $1.19 dividend. The ex-dividend date of this dividend was Monday, November 20th. This represents a $4.76 annualized dividend and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio (DPR) is 35.34%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Kingdom Financial Group LLC. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 258.0% during the third quarter, Holdings Channel reports. The fund owned 9,268 shares of the company’s stock after purchasing an additional 6,679 shares during the quarter. Johnson & Johnson comprises 1.4% of Kingdom Financial Group LLC.’s portfolio, making the stock its 17th biggest holding. Kingdom Financial Group LLC.’s holdings in Johnson & Johnson were worth $1,443,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Hibernia Wealth Partners LLC acquired a new stake in Johnson & Johnson in the 3rd quarter worth about $27,000. Atlantic Private Wealth LLC acquired a new stake in Johnson & Johnson in the 1st quarter worth about $32,000. FNY Investment Advisers LLC acquired a new stake in Johnson & Johnson in the 3rd quarter worth about $37,000. VitalStone Financial LLC acquired a new stake in Johnson & Johnson in the 2nd quarter worth about $48,000. Finally, Horizons Wealth Management lifted its stake in shares of Johnson & Johnson by 1,730.0% in the 2nd quarter. Horizons Wealth Management now owns 366 shares of the company’s stock valued at $61,000 after purchasing an additional 346 shares in the last quarter. Institutional investors and hedge funds own 68.40% of the company’s stock.

Johnson & Johnson Trading Up 0.1 %

NYSE:JNJ opened at $156.35 on Thursday. Johnson & Johnson has a 12-month low of $144.95 and a 12-month high of $180.93. The firm has a market capitalization of $376.38 billion, a P/E ratio of 11.61, a P/E/G ratio of 3.18 and a beta of 0.57. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.21 and a quick ratio of 0.96. The business has a 50 day simple moving average of $152.40 and a 200 day simple moving average of $159.62.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Tuesday, October 17th. The company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.52 by $0.14. Johnson & Johnson had a return on equity of 37.14% and a net margin of 36.32%. The business had revenue of $21.35 billion during the quarter, compared to analyst estimates of $21 billion. Equities research analysts predict that Johnson & Johnson will post 9.96 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 5th. Investors of record on Tuesday, November 21st were given a dividend of $1.19 per share. The ex-dividend date was Monday, November 20th. This represents a $4.76 dividend on an annualized basis and a yield of 3.04%. Johnson & Johnson’s dividend payout ratio is currently 35.34%.

Analysts Set New Price Targets

Several research firms have recently weighed in on JNJ. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research note on Monday, December 18th. Wells Fargo & Company downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $170.00 to $163.00 in a report on Wednesday, December 13th. Raymond James dropped their target price on Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating on the stock in a report on Wednesday, October 18th. UBS Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their target price for the company from $167.00 to $180.00 in a report on Friday, December 1st. Finally, HSBC initiated coverage on Johnson & Johnson in a report on Wednesday, September 6th. They set a “hold” rating and a $175.00 price objective on the stock. Eight analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $168.75.

Get Our Latest Research Report on Johnson & Johnson

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

M&R Capital Management Inc. reduced its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 3.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,635 shares of the company’s stock after selling 811 shares during the quarter. Johnson & Johnson makes up about 1.1% of M&R Capital Management Inc.’s investment portfolio, making the stock its 23rd biggest holding. M&R Capital Management Inc.’s holdings in Johnson & Johnson were worth $3,837,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Moneta Group Investment Advisors LLC grew its stake in Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after buying an additional 54,326,454 shares during the last quarter. Norges Bank acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $4,609,399,000. Capital International Investors boosted its holdings in shares of Johnson & Johnson by 62.7% during the second quarter. Capital International Investors now owns 27,825,795 shares of the company’s stock valued at $4,605,627,000 after acquiring an additional 10,724,110 shares during the period. Journey Strategic Wealth LLC boosted its holdings in shares of Johnson & Johnson by 161,420.2% during the second quarter. Journey Strategic Wealth LLC now owns 7,276,483 shares of the company’s stock valued at $1,204,404,000 after acquiring an additional 7,271,978 shares during the period. Finally, Providence Capital Advisors LLC boosted its holdings in shares of Johnson & Johnson by 141,974.0% during the first quarter. Providence Capital Advisors LLC now owns 4,750,956 shares of the company’s stock valued at $30,651,000 after acquiring an additional 4,747,612 shares during the period. 68.40% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

JNJ has been the subject of several analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $178.00 price target on shares of Johnson & Johnson in a report on Friday, December 1st. TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $174.00 to $171.00 and set an “equal weight” rating for the company in a report on Wednesday, October 18th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 26th. Finally, Wells Fargo & Company downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $168.75.

Read Our Latest Stock Analysis on Johnson & Johnson

Johnson & Johnson Price Performance

JNJ stock opened at $156.46 on Wednesday. The company has a current ratio of 1.21, a quick ratio of 0.96 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a one year low of $144.95 and a one year high of $180.93. The firm has a market capitalization of $376.64 billion, a PE ratio of 11.62, a P/E/G ratio of 3.17 and a beta of 0.57. The firm has a 50-day moving average of $152.51 and a two-hundred day moving average of $159.79.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.14. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. The company had revenue of $21.35 billion during the quarter, compared to analyst estimates of $21 billion. On average, analysts forecast that Johnson & Johnson will post 9.97 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 5th. Stockholders of record on Tuesday, November 21st were issued a $1.19 dividend. The ex-dividend date of this dividend was Monday, November 20th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio is 35.34%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Vision Capital Management Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.6% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 52,406 shares of the company’s stock after selling 326 shares during the quarter. Johnson & Johnson makes up 1.5% of Vision Capital Management Inc.’s investment portfolio, making the stock its 20th largest holding. Vision Capital Management Inc.’s holdings in Johnson & Johnson were worth $8,674,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Farmers & Merchants Investments Inc. lifted its holdings in Johnson & Johnson by 1.2% in the 2nd quarter. Farmers & Merchants Investments Inc. now owns 164,235 shares of the company’s stock worth $27,184,000 after purchasing an additional 1,954 shares during the last quarter. FIDELIS iM LLC acquired a new stake in Johnson & Johnson in the 2nd quarter worth approximately $207,000. Pursue Wealth Partners LLC acquired a new stake in Johnson & Johnson in the 2nd quarter worth approximately $881,000. Choate Investment Advisors lifted its holdings in Johnson & Johnson by 16.6% in the 2nd quarter. Choate Investment Advisors now owns 79,544 shares of the company’s stock worth $13,166,000 after purchasing an additional 11,330 shares during the last quarter. Finally, BDO Wealth Advisors LLC lifted its holdings in Johnson & Johnson by 3.5% in the 2nd quarter. BDO Wealth Advisors LLC now owns 16,998 shares of the company’s stock worth $2,813,000 after purchasing an additional 576 shares during the last quarter. 68.40% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have commented on JNJ. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Morgan Stanley dropped their price target on Johnson & Johnson from $174.00 to $171.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 18th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Atlantic Securities lifted their price target on Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research report on Friday, August 4th. Finally, TheStreet raised Johnson & Johnson from a “c+” rating to a “b+” rating in a research report on Monday, August 21st. Eight equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $169.19.

Read Our Latest Analysis on Johnson & Johnson

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $145.60 on Monday. The business’s fifty day moving average price is $158.90 and its two-hundred day moving average price is $161.94. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $181.04. The stock has a market capitalization of $378.41 billion, a price-to-earnings ratio of 10.81, a price-to-earnings-growth ratio of 2.94 and a beta of 0.55. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 5th. Shareholders of record on Tuesday, November 21st will be given a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 3.27%. The ex-dividend date of this dividend is Monday, November 20th. Johnson & Johnson’s dividend payout ratio (DPR) is 35.34%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Monument Capital Management acquired a new stake in Johnson & Johnson (NYSE:JNJ – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,332 shares of the company’s stock, valued at approximately $386,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Atlantic Private Wealth LLC acquired a new position in shares of Johnson & Johnson during the first quarter worth approximately $32,000. Dark Forest Capital Management LP lifted its position in Johnson & Johnson by 1,044.4% in the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after purchasing an additional 188 shares during the period. Ruedi Wealth Management Inc. acquired a new stake in Johnson & Johnson in the fourth quarter worth approximately $42,000. Kepos Capital LP acquired a new stake in Johnson & Johnson in the fourth quarter worth approximately $45,000. Finally, 25 LLC acquired a new stake in Johnson & Johnson in the first quarter worth approximately $55,000. 68.40% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $155.75 on Monday. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $404.79 billion, a P/E ratio of 31.53, a price-to-earnings-growth ratio of 3.15 and a beta of 0.55. The firm has a 50 day moving average of $165.97 and a 200-day moving average of $162.29. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The business had revenue of $25.53 billion during the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. Johnson & Johnson’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.59 earnings per share. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were issued a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 3.06%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 96.36%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on JNJ. TheStreet raised Johnson & Johnson from a “c+” rating to a “b+” rating in a report on Monday, August 21st. Credit Suisse Group boosted their target price on shares of Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, September 18th. Finally, HSBC assumed coverage on shares of Johnson & Johnson in a report on Wednesday, September 6th. They issued a “hold” rating and a $175.00 price objective for the company. Nine investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Hold” and an average price target of $170.65.

Get Our Latest Stock Report on JNJ

Insiders Place Their Bets

In other news, insider William Hait sold 14,698 shares of the business’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the transaction, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider William Hait sold 14,698 shares of the business’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the sale, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.